Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.58 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MC4R | P32245 | 1/20 | 0.47 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.46 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14924019 | 0.88 | SIGMAR1 (0.59) | SIGMAR1CYP1A2CYP2D6TMEM97KCNJ1 | |
| SCHEMBL10169516 | 0.87 | HRH3 (0.59) | SIGMAR1CYP1A2KCNJ1KCNH2HRH3 | |
| SCHEMBL10169518 | 0.87 | HRH3 (0.65) | SIGMAR1CYP1A2HRH3MBTD1L3MBTL3 | |
| SCHEMBL14924046 | 0.86 | HRH3 (0.65) | SIGMAR1CYP1A2HRH3MBTD1L3MBTL3 | |
| SCHEMBL6894415 | 0.84 | LMNA (0.68) | SIGMAR1HRH3LMNAMC4R | |
| SCHEMBL13595098 | 0.83 | MEN1 (0.47) | SIGMAR1CYP1A2CYP2D6TMEM97KCNJ1 | |
| SCHEMBL4547889 | 0.83 | SIGMAR1 (0.59) | SIGMAR1KCNH2HRH3L3MBTL3L3MBTL1 | |
| SCHEMBL18389943 | 0.81 | SIGMAR1 (0.67) | SIGMAR1CYP1A2CYP2D6TMEM97HRH3 | |
| SCHEMBL1509554 | 0.81 | LMNA (0.70) | SIGMAR1CYP1A2CYP2D6TMEM97KCNJ1 | |
| SCHEMBL14924021 | 0.81 | KDM4E (0.48) | SIGMAR1KCNJ1KCNH2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE46511-E1 | Fused pyrimidine derivatives for inhibition of tyrosine kinase activity | HANMI SCIENCE CO., LTD. (KR) | 2017-08-15 | — | — | US | disclosed |
| US-RE46511-E1 | Fused pyrimidine derivatives for inhibition of tyrosine kinase activity | HANMI SCIENCE CO., LTD. (KR) | 2017-08-15 | — | — | US | disclosed |
| US-20160229868-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | HANMI SCIENCE CO., LTD (KR) | 2016-08-11 | — | — | US | disclosed |
| US-9345719-B2 | Fused pyrimidine derivatives for inhibition of tyrosine kinase activity | HANMI SCIENCE CO., LTD. (KR) | 2016-05-24 | — | — | US | disclosed |
| US-8957065-B2 | Fused pyrimidine derivatives for inhibition of tyrosine kinase activity | HANMI SCIENCE CO., LTD (KR) | 2015-02-17 | — | — | US | disclosed |
| US-20150045324-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | HANMI SCIENCE CO., LTD (KR) | 2015-02-12 | — | — | US | disclosed |
| US-20130116213-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | HANMI SCIENCE CO., LTD. (KR) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229868-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | LCK, LTK, FYN | SIGMAR1 4821/4885CYP1A2 4648/4885CYP2D6 4459/4885 |
| US-20150045324-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | LCK, FYN, TYK2 | SIGMAR1 4807/4885CYP1A2 4693/4885CYP2D6 4505/4885 |
| US-20130116213-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | LCK, FYN, TYK2 | SIGMAR1 4807/4885CYP1A2 4693/4885CYP2D6 4505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.